- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00436332
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC)
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
OBJECTIVES:
Primary
- Determine overall survival of patients with stage IIIB or IV bronchioloalveolar carcinoma (BAC) or adenocarcinoma with BAC features treated with erlotinib hydrochloride and bevacizumab.
Secondary
- Determine the progression-free survival of patients treated with this regimen.
- Compare, preliminarily, response as assessed by RECIST criteria vs response as assessed by a central computer-assisted image-analysis system in patients with measurable disease treated with this regimen.
- Assess the frequency and severity of toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral erlotinib hydrochloride once daily on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for up to 2 years.
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
California
-
Antioch, California, Stati Uniti, 94531
- Kaiser Permanente - Deer Valley
-
Berkeley, California, Stati Uniti, 94704
- Alta Bates Summit Comprehensive Cancer Center
-
Burlingame, California, Stati Uniti, 94010
- Peninsula Medical Center
-
Fremont, California, Stati Uniti, 94538
- Kaiser Permanente - Fremont
-
Hayward, California, Stati Uniti, 94545
- Kaiser Permanente Medical Center - Hayward
-
Marysville, California, Stati Uniti, 95901
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP
-
Oakland, California, Stati Uniti, 94611
- Kaiser Permanente Medical Center - Oakland
-
Pleasanton, California, Stati Uniti, 94588
- Valley Medical Oncology Consultants - Pleasanton
-
Redwood City, California, Stati Uniti, 94063
- Kaiser Permanente Medical Center - Redwood City
-
Richmond, California, Stati Uniti, 94801
- Kaiser Permanente Medical Center - Richmond
-
Roseville, California, Stati Uniti, 95661
- Kaiser Permanente Medical Center - Roseville
-
Sacramento, California, Stati Uniti, 95817
- University of California Davis Cancer Center
-
Sacramento, California, Stati Uniti, 95823
- South Sacramento Kaiser-Permanente Medical Center
-
Sacramento, California, Stati Uniti, 95825
- Kaiser Permanente Medical Center - Sacramento
-
San Francisco, California, Stati Uniti, 94115
- Kaiser Permanente Medical Center - San Francisco Geary Campus
-
San Francisco, California, Stati Uniti, 94118
- California Pacific Medical Center - California Campus
-
San Jose, California, Stati Uniti, 95119
- Kaiser Permanente Medical Center - Santa Teresa
-
San Rafael, California, Stati Uniti, 94903
- Sutter Health - Western Division Cancer Research Group
-
San Rafael, California, Stati Uniti, 94903
- Kaiser Foundation Hospital - San Rafael
-
Santa Clara, California, Stati Uniti, 95051
- Kaiser Permanente Medical Center - Santa Clara Kiely Campus
-
Santa Rosa, California, Stati Uniti, 95403
- Kaiser Permanente Medical Center - Santa Rosa
-
South San Francisco, California, Stati Uniti, 94080
- Kaiser Permanente Medical Center - South San Francisco
-
Stockton, California, Stati Uniti, 95210
- Kaiser Permanente Medical Facility - Stockton
-
Truckee, California, Stati Uniti, 96161
- Tahoe Forest Cancer Center
-
Vacaville, California, Stati Uniti, 95688
- Kaiser Permanente Medical Center - Vacaville
-
Vallejo, California, Stati Uniti, 94589
- Sutter Solano Medical Center
-
Vallejo, California, Stati Uniti, 94589
- Kaiser Permanente Medical Center - Vallejo
-
Walnut Creek, California, Stati Uniti, 94596
- Kaiser Permanente Medical Center - Walnut Creek
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Stati Uniti, 30342-1611
- Northside Hospital Cancer Center
-
Atlanta, Georgia, Stati Uniti, 30342-1701
- Saint Joseph's Hospital of Atlanta
-
Atlanta, Georgia, Stati Uniti, 30342
- CCOP - Atlanta Regional
-
Austell, Georgia, Stati Uniti, 30106
- WellStar Cobb Hospital
-
Columbus, Georgia, Stati Uniti, 31904
- John B. Amos Cancer Center
-
Decatur, Georgia, Stati Uniti, 30033
- Charles B. Eberhart Cancer Center at DeKalb Medical Center
-
Fayetteville, Georgia, Stati Uniti, 30214
- Piedmont Fayette Hospital
-
Gainesville, Georgia, Stati Uniti, 30501
- Northeast Georgia Medical Center
-
Lawrenceville, Georgia, Stati Uniti, 30045
- Gwinnett Medical Center
-
Marietta, Georgia, Stati Uniti, 30060
- Kennestone Cancer Center at Wellstar Kennestone Hospital
-
Riverdale, Georgia, Stati Uniti, 30274-2600
- Southern Regional Medical Center
-
Rome, Georgia, Stati Uniti, 30165
- Harbin Clinic Cancer Center - Medical Oncology
-
-
Hawaii
-
Honolulu, Hawaii, Stati Uniti, 96819
- Kaiser Permanente - Moanalua Medical Center and Clinic
-
-
Illinois
-
Decatur, Illinois, Stati Uniti, 62526
- Decatur Memorial Hospital Cancer Care Institute
-
Maywood, Illinois, Stati Uniti, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
Springfield, Illinois, Stati Uniti, 62781-0001
- Regional Cancer Center at Memorial Medical Center
-
-
Kansas
-
Chanute, Kansas, Stati Uniti, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Stati Uniti, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Stati Uniti, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Stati Uniti, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Stati Uniti, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Stati Uniti, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Stati Uniti, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Stati Uniti, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, Stati Uniti, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Stati Uniti, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Stati Uniti, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Stati Uniti, 67401
- Cancer Center of Kansas, PA - Salina
-
Salina, Kansas, Stati Uniti, 67401
- Tammy Walker Cancer Center at Salina Regional Health Center
-
Topeka, Kansas, Stati Uniti, 66606
- Cotton-O'Neil Cancer Center
-
Wellington, Kansas, Stati Uniti, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Stati Uniti, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Stati Uniti, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Stati Uniti, 67214
- CCOP - Wichita
-
Wichita, Kansas, Stati Uniti, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Stati Uniti, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Stati Uniti, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536-0093
- Lucille P. Markey Cancer Center at University of Kentucky
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Stati Uniti, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Stati Uniti, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, Stati Uniti, 49307
- Mecosta County Medical Center
-
Dearborn, Michigan, Stati Uniti, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Flint, Michigan, Stati Uniti, 48503
- Hurley Medical Center
-
Flint, Michigan, Stati Uniti, 48503
- Genesys Hurley Cancer Institute
-
Grand Blanc, Michigan, Stati Uniti, 48439
- Genesys Regional Medical Center
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Stati Uniti, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, Stati Uniti, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Jackson, Michigan, Stati Uniti, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, Stati Uniti, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Stati Uniti, 48154
- St. Mary Mercy Hospital
-
Muskegon, Michigan, Stati Uniti, 49443
- Mercy General Health Partners
-
Pontiac, Michigan, Stati Uniti, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Stati Uniti, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, Stati Uniti, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Traverse City, Michigan, Stati Uniti, 49684
- Munson Medical Center
-
Warren, Michigan, Stati Uniti, 48093
- St. John Macomb Hospital
-
Wyoming, Michigan, Stati Uniti, 49519
- Metro Health Hospital
-
-
Montana
-
Billings, Montana, Stati Uniti, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Stati Uniti, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Stati Uniti, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, Stati Uniti, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, Stati Uniti, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Stati Uniti, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Stati Uniti, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, Stati Uniti, 59405-5309
- Big Sky Oncology
-
Great Falls, Montana, Stati Uniti, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre, Montana, Stati Uniti, 59501
- Northern Montana Hospital
-
Helena, Montana, Stati Uniti, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Stati Uniti, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, Stati Uniti, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, Stati Uniti, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, Stati Uniti, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, Stati Uniti, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Carolina
-
Goldsboro, North Carolina, Stati Uniti, 27534
- Wayne Memorial Hospital, Incorporated
-
Hendersonville, North Carolina, Stati Uniti, 28791
- Pardee Memorial Hospital
-
-
Ohio
-
Bellefontaine, Ohio, Stati Uniti, 43311
- Mary Rutan Hospital
-
Chillicothe, Ohio, Stati Uniti, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, Stati Uniti, 43214-3998
- Riverside Methodist Hospital Cancer Care
-
Columbus, Ohio, Stati Uniti, 43222
- Mount Carmel Health - West Hospital
-
Columbus, Ohio, Stati Uniti, 43215
- CCOP - Columbus
-
Columbus, Ohio, Stati Uniti, 43215
- Grant Medical Center Cancer Care
-
Columbus, Ohio, Stati Uniti, 43228
- Doctors Hospital at Ohio Health
-
Delaware, Ohio, Stati Uniti, 43015
- Grady Memorial Hospital
-
Lancaster, Ohio, Stati Uniti, 43130
- Fairfield Medical Center
-
Marietta, Ohio, Stati Uniti, 45750
- Strecker Cancer Center at Marietta Memorial Hospital
-
Mount Vernon, Ohio, Stati Uniti, 43050
- Knox Community Hospital
-
Newark, Ohio, Stati Uniti, 43055
- Licking Memorial Cancer Care Program at Licking Memorial Hospital
-
Springfield, Ohio, Stati Uniti, 45505
- Community Hospital of Springfield and Clark County
-
Westerville, Ohio, Stati Uniti, 43081
- Mount Carmel St. Ann's Cancer Center
-
Zanesville, Ohio, Stati Uniti, 43701
- Genesis - Good Samaritan Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Utah
-
American Fork, Utah, Stati Uniti, 84003
- American Fork Hospital
-
Cedar City, Utah, Stati Uniti, 84720
- Sandra L. Maxwell Cancer Center
-
Logan, Utah, Stati Uniti, 84321
- Logan Regional Hospital
-
Murray, Utah, Stati Uniti, 84157
- Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
-
Ogden, Utah, Stati Uniti, 84403
- Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
-
Provo, Utah, Stati Uniti, 84604
- Utah Valley Regional Medical Center - Provo
-
Saint George, Utah, Stati Uniti, 84770
- Dixie Regional Medical Center - East Campus
-
Salt Lake City, Utah, Stati Uniti, 84143
- LDS Hospital
-
Salt Lake City, Utah, Stati Uniti, 84106
- Utah Cancer Specialists at UCS Cancer Center
-
-
Washington
-
Bellingham, Washington, Stati Uniti, 98225
- St. Joseph Cancer Center
-
Bremerton, Washington, Stati Uniti, 98310
- Olympic Hematology and Oncology
-
Kennewick, Washington, Stati Uniti, 99336
- Columbia Basin Hematology
-
Mount Vernon, Washington, Stati Uniti, 98274
- Skagit Valley Hospital Cancer Care Center
-
Poulsbo, Washington, Stati Uniti, 98370
- Harrison Poulsbo Hematology and Onocology
-
Seattle, Washington, Stati Uniti, 98109
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Stati Uniti, 98104
- Harborview Medical Center
-
Seattle, Washington, Stati Uniti, 98104
- Minor and James Medical, PLLC
-
Seattle, Washington, Stati Uniti, 98112
- Group Health Central Hospital
-
Seattle, Washington, Stati Uniti, 98122-4307
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Seattle, Washington, Stati Uniti, 98195
- University Cancer Center at University of Washington Medical Center
-
Spokane, Washington, Stati Uniti, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Stati Uniti, 99218
- Evergreen Hematology and Oncology, PS
-
Wenatchee, Washington, Stati Uniti, 98801-2028
- Wenatchee Valley Medical Center
-
-
Wyoming
-
Sheridan, Wyoming, Stati Uniti, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Biopsy-proven* bronchioloalveolar carcinoma (BAC) or BAC variants (e.g., adenocarcinoma with BAC features, BAC with invasive adenocarcinoma) meeting the following criteria:
- Incompletely resected or unresectable disease
- No component of squamous cell carcinoma
Disease staged as 1 of the following:
- Stage IIIB disease (T4 [cytologically confirmed malignant pleural effusion OR pleural tumor foci that are separate from direct pleural invasion by the primary tumor], any N, M0)
Stage IV disease (any T, any N, M1 [distant metastases present])
- Recurrent disease in a separate lobe after prior resection within the past 5 years; multifocal lesions in > 1 lobe; or any disease that is recurrent after surgery or radiotherapy is considered stage IV disease
- Tumor may be multifocal or diffuse NOTE: *Cytology specimens, including bronchial brushing, washings, or fine needle aspiration specimens, alone are not acceptable for diagnosis
Measurable or nonmeasurable disease by chest CT scan
- Pleural effusions, ascites, and laboratory parameters are not acceptable as only evidence of disease
- Disease must be present outside field of prior radiotherapy OR a new lesion must be inside port
- Treated brain metastases allowed provided the patient is asymptomatic and do not require steroids
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-2
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Total bilirubin normal
- AST or AST ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
- Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases are present)
- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
- Urine protein:creatinine ratio ≤ 0.5 OR urine protein < 1 g by 24-hour urine collection
- Willing to provide prior smoking history
- No hemoptysis ≥ ½ teaspoon within the past 28 days
- No clinical history of pulmonary or upper respiratory hemorrhage > grade 2 within the past 6 months or > grade 1 within the past 28 days
- No history of thromboses or hemorrhage, including hemorrhagic or thrombotic stroke, or other CNS bleeding
- No uncontrolled hypertension
- No serious nonhealing wound, ulcer, or bone fracture
No other prior malignancy except for any of the following:
- Adequately treated basal cell or squamous cell skin cancer
- In situ cervical cancer
- Adequately treated stage I or II cancer that is currently in complete remission
- Any other cancer from which the patient has been disease free for 5 years
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior therapy
- At least 28 days since prior radiotherapy (14 days for palliative radiotherapy)
- At least 28 days since prior surgery (thoracic or other major surgeries)
- More than 7 days since prior fine-needle aspiration or core biopsy
- At least 28 days since prior systemic chemotherapy or biologic therapy
- No prior gefitinib hydrochloride, erlotinib hydrochloride, or bevacizumab
- No other prior anti-epidermal growth factor receptor or anti-vascular endothelial growth factor therapies
- Concurrent stable, therapeutic anticoagulation therapy allowed (i.e., warfarin or low molecular weight heparin), provided the patient has no history of bleeding complications on anticoagulation or an inability to establish a stable therapeutic regimen for anticoagulation
- No other concurrent anticancer therapy, including surgery, chemotherapy, hormone therapy, biologic therapy, or radiotherapy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Erlotinib and Bevacizumab
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Overall Survival
Lasso di tempo: From date of registration to maximum of 3 years
|
From date of registration to maximum of 3 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Progression-free Survival
Lasso di tempo: From date of registration to maximum of 3 years
|
From date of registration to maximum of 3 years
|
|
Response as Assessed by RECIST Criteria vs Central Computer-assisted Image-analysis System in Patients With Measurable Disease
Lasso di tempo: From date of registration to maximum of 3 years
|
Images for response assessed by the central computer-assisted image-analysis system were never collected.
|
From date of registration to maximum of 3 years
|
Frequency and Severity of Toxicities
Lasso di tempo: From date of registration to maximum of 3 years
|
From date of registration to maximum of 3 years
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- West HJ, Moon J, Hirsch FR, et al.: SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). [Abstract] J Clin Oncol 30 (Suppl 15): A-7517, 2012.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie
- Malattie polmonari
- Neoplasie per sede
- Adenocarcinoma
- Carcinoma
- Neoplasie, ghiandolari ed epiteliali
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Adenocarcinoma del polmone
- Neoplasie polmonari
- Adenocarcinoma, bronchiolo-alveolare
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Inibitori della chinasi proteica
- Erlotinib cloridrato
- Bevacizumab
Altri numeri di identificazione dello studio
- CDR0000529756
- U10CA032102 (Sovvenzione/contratto NIH degli Stati Uniti)
- S0635 (Altro identificatore: SWOG)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro ai polmoni
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su bevacizumab
-
National Cancer Institute (NCI)Attivo, non reclutanteCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Cistodenocarcinoma ovarico a cellule chiare | Adenocarcinoma endometrioide ovarico | Cistodenocarcinoma sieroso ovarico | Adenocarcinoma endometriale a cellule chiare | Adenocarcinoma... e altre condizioniStati Uniti
-
M.D. Anderson Cancer CenterReclutamentoCarcinoma epatocellulare in stadio IB AJCC v8 | Carcinoma epatocellulare in stadio II AJCC v8 | Carcinoma epatocellulare resecabile | Carcinoma epatocellulare stadio I AJCC v8 | Stadio IA Carcinoma epatocellulare AJCC v8Stati Uniti
-
National Cancer Institute (NCI)CompletatoAdenocarcinoma cervicale | Carcinoma adenosquamoso cervicale | Carcinoma a cellule squamose della cervice, non altrimenti specificato | Stadio IVA Cancro cervicale AJCC v6 e v7 | Carcinoma cervicale ricorrente | Cancro cervicale in stadio IV AJCC v6 e v7 | Stadio IVB Cancro cervicale AJCC v6 e v7Stati Uniti
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ReclutamentoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Adenocarcinoma endometrioide ovarico | Adenocarcinoma ovarico a cellule chiare | Adenocarcinoma della tuba di Falloppio | Adenocarcinoma sieroso delle tube di Falloppio | Adenocarcinoma... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteMelanoma cutaneo di stadio IV AJCC v6 e v7 | Melanoma cutaneo in stadio IIIC AJCC v7 | Melanoma non resecabileStati Uniti
-
National Cancer Institute (NCI)NRG OncologyCompletatoGlioblastoma | Gliosarcoma | Glioblastoma ricorrente | Oligodendrogliomi | Glioblastoma a cellule giganti | Neoplasia cerebrale ricorrenteStati Uniti, Canada
-
National Cancer Institute (NCI)ReclutamentoSarcoma metastatico della parte molle alveolare | Sarcoma della parte molle alveolare non resecabileStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteAdenocarcinoma endometrioide ovarico | Adenocarcinoma sieroso peritoneale primario di alto grado | Adenocarcinoma endometrioide delle tube di Falloppio | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Adenocarcinoma sieroso ovarico... e altre condizioniStati Uniti, Canada
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletatoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Carcinoma ovarico resistente al platino | Carcinoma ovarico... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteGlioblastoma ricorrenteStati Uniti